King's Research Portal

DOI:

[10.1016/j.vph.2012.08.002](https://doi.org/10.1016/j.vph.2012.08.002)

Document Version

Early version, also known as pre-print

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Starr, A., Hussein, D., & Nandi, M. (2013). The regulation of vascular tetrahydrobiopterin bioavailability. *VASCULAR PHARMACOLOGY*, 58(3), 219-230. <https://doi.org/10.1016/j.vph.2012.08.002>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

The regulation of vascular tetrahydrobiopterin bioavailability

Anna Starr, Dania Hussein, Manasi Nandi*

Pharmacology and Therapeutics Group, Institute of Pharmaceutical Science, School of Biomedical Sciences, King's College London, Franklin Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom

*Corresponding author:

Tel: +44 (0) 207 848 4446

Fax: +44 (0) 207 848 4500

Email: manasi.nandi@kcl.ac.uk

Abstract

6R L-erythro-5,6,7,8-tetrahydrobiopterin (BH₄) is an essential cofactor for several enzymes including phenylalanine hydroxylase and the nitric oxide synthases (NOS). Oral supplementation of BH₄ has been successfully employed to treat subsets of patients with hyperphenylalaninaemia. More recently, research efforts have focussed on understanding whether BH₄ supplementation may also be efficacious in cardiovascular disorders that are underpinned by reduced nitric oxide bioavailability. Whilst numerous preclinical and clinical studies have demonstrated a positive association between enhanced BH₄ and vascular function, the efficacy of orally administered BH₄ in human cardiovascular disease remains unclear. Furthermore, interventions that limit BH₄ bioavailability may provide benefit in diseases where nitric oxide over production contributes to pathology. This review describes the pathways involved in BH₄ bio-regulation and discusses other endogenous mechanisms that could be harnessed therapeutically to manipulate vascular BH₄ levels.

Key words:

Tetrahydrobiopterin; GTP cyclohydrolase 1; Nitric Oxide Synthase; Endothelial

Word Count: 5499

1. Introduction

6*R* L-erythro-5,6,7,8-tetrahydrobiopterin (BH₄) has, in recent years, garnered considerable attention as a therapeutic target for a number of pathologies, notably neurological and cardiovascular diseases. The ability of BH₄ to affect such a diverse range of biological systems can be attributed to its essential cofactor role for numerous enzyme families, namely the aromatic amino acid hydroxylases (AAAH) phenylalanine, tyrosine and tryptophan hydroxylase^{1,2}, the nitric oxide synthases (neuronal/ NOS 1, inducible/NOS 2, endothelial/NOS3)^{3,4} and alkylglycerol mono-oxygenase (or glyceryl ether monooxygenase - GEMO)^{5,6}. It is also likely that there are a number of other biological roles for BH₄ which are yet to be determined⁷.

The pharmacological enhancement of intracellular BH₄ levels holds therapeutic promise for a number of cardiovascular disorders underpinned by reduced nitric oxide (NO) and thus endothelial dysfunction. Conversely, attenuating the rise in intracellular BH₄ which occurs in response to proinflammatory stimulation would be of benefit in diseases such as inflammatory pain and circulatory collapse as observed in septic shock patients. This review summarises the current evidence supporting the modulation of BH₄ levels and discusses alternate strategies to regulate its bioavailability at an intracellular level.

2. BH₄ reaction mechanisms

Endogenous BH₄ levels are regulated by a number of highly conserved synthetic and recycling enzymes (summarised in Fig. 1) that ensure intracellular BH₄ levels are maintained at or below saturating levels for enzymes that require it as a cofactor⁸.

These include the:

- i) 'De novo biosynthetic pathway' utilising GTP as a substrate
- ii) 'Regeneration/recycling pathway' which regenerates BH₄ following its bioconversion during the reactions catalysed by AAAH and GEMO
- iii) 'Salvage pathway' which can regenerate BH₄ from 7,8 dihydrobiopterin (BH₂).

The *de novo* biosynthesis of BH₄ proceeds in a Zn²⁺, Mg²⁺ and NADPH-dependent manner from GTP via two reaction intermediates; 7,8-dihydroneopterin triphosphate and 6-pyruvoyl-tetrahydropterin. The enzymes involved in these reactions are; GTP cyclohydrolase 1 (GCH1), 6-pyruvoyl tetrahydropterin synthase (PTPS) and sepiapterin reductase (SR), with the latter step believed to occur in two stages with different reaction intermediates⁸⁻¹¹ (Fig. 1). Of these biosynthetic enzymes,

GCH1 commonly forms the rate limiting step, and thus represents a tractable target for the pharmacological manipulation of endogenous BH₄ levels.

Figure 1: BH₄ biosynthetic and regulatory pathways. GCH1, GTP cyclohydrolase 1; PTPS, Pyruvoyl tetrahydropterin synthase; SR, sepiapterin reductase; CR, carbonyl reductase; PAH, phenylalanine hydroxylase; NOS, nitric oxide synthase; PCD/dCoH1 pterin-4a-carbinolamine dehydratase; dCoH1 dimerization cofactor of HNF-1; DHPR, dihydropteridine reductase; DHFR, dihydrofolate reductase. *Sepiapterin reductase mediated step during de novo biosynthesis is believed to occur in two stages with two different reaction intermediates, but this has been excluded from the diagram for simplification. †For simplification, tyrosine hydroxylase, tryptophan hydroxylase and glyceryl ether monooxygenase have been excluded from the diagram.

Enzymes for which BH₄ serves as a cofactor, are all mixed function mono-oxygenases. Mono-oxygenases utilise molecular oxygen during the reaction, incorporating one oxygen atom into the substrate whilst the second oxygen atom is reduced to water. The reaction mechanisms of enzymes that use BH₄ as a cofactor have been summarised in extensive reviews and will not be detailed further here^{8, 10}. However, it is important to note that the BH₄ turnover products and regeneration reactions differ for the different enzyme families (Fig. 1). During the reactions catalysed by PAH and other AAAH, BH₄ is initially oxidised to tetrahydrobiopterin-4a-carbinolamine and two further enzymatic steps are involved in the subsequent dehydration and reduction back to BH₄.

In contrast, it is clear that NOS uses BH₄ in a different manner. Numerous functions of BH₄ have been proposed, including structural stabilisation of the NOS dimer and eliciting conformational changes that increase L-arginine binding¹²⁻¹⁶. However, current opinion suggests that a key biochemical

mechanism by which BH₄ supports NOS mediated catalysis, is through electron donation to the heme iron located within the NOS oxygenase domain¹⁷⁻¹⁹.

During NOS mediated catalysis, electrons originating from the NOS reductase domain, are carried to the NOS oxygenase domain, where two successive mono-oxygenase reactions occur. These reactions involve the initial oxidation of L-arginine to the intermediate N-hydroxy-L-arginine (NOHA), which is then further converted to the end products L-citrulline and nitric oxide (NO)²⁰. Each of these mono-oxygenase reactions requires BH₄.

The oxygenase domain contains a ferric heme group and BH₄ has been shown to bind in close proximity to this group²¹. Electrons originating from the NOS reductase domain reduce the ferric heme to a ferrous state, enabling O₂ to bind. This leads to the formation of a ferric heme-superoxy intermediate (Fe^{III}-O₂⁻). It is believed that BH₄ donates an electron at this point, thus reducing the ferric heme-superoxy species to form a heme-oxy species facilitating L-arginine oxidation. During this process, BH₄ itself becomes an enzyme bound BH₃⁺ radical^{18, 22-26}. In contrast to AAAH mediated catalysis, BH₄ does not undergo regeneration by external enzymes, but rather is regenerated from the protonated BH₃⁺ radical by electrons supplied from the NOS reductase domain.

3. BH₄ oxidation and NOS 'uncoupling'

The pathophysiological importance of BH₄ during NOS mediated catalysis is apparent in situations where BH₄ bioavailability is low or absent (due to oxidation or insufficient biosynthesis/recycling). Under these circumstances, BH₄ is no longer available to reduce the ferric heme-superoxy species in NOS, leading to its dissociation and the release of superoxide (O₂⁻) – a phenomenon termed 'NOS uncoupling'. Thus, BH₄ deficiency and eNOS uncoupling contributes to endothelial dysfunction not only by directly reducing NO production but also by increasing NO scavenging due to O₂⁻ formation. This potential for NOS to generate reactive oxygen species is thought to further potentiate vascular dysfunction and highlights the importance of sustaining sufficient BH₄ levels for full NOS functionality, within the intracellular pool.

BH₄ is itself highly susceptible to auto-oxidation, through its interaction with reactive oxygen species – in particular peroxynitrite (ONOO⁻), which is formed via the interaction of NO and O₂⁻. During the reaction with ONOO⁻, BH₄ is believed to initially be converted to a BH₃⁺ radical which can be further oxidised to BH₂, although this final step can be prevented by ascorbate²⁷.

A further potential detrimental consequence of BH₄ oxidation, is that its oxidation product, BH₂ can bind to NOS with approximately the same affinity as BH₄, but serves no cofactor function. BH₂ may

therefore compete with, or potentially displace, BH₄ binding to NOS²⁸. Thus, the ratio of BH₄:BH₂ in biological samples, rather than just BH₄ alone, may be considered a more important determinant of final NOS functionality²⁹.

The function of the recycling enzyme dihydrofolate reductase (DHFR) in sustaining BH₄ levels is likely to become especially important in situations where BH₄ has been subject to oxidative inactivation. It is known that DHFR regenerates BH₄ from BH₂³⁰ (Figure 1) and biopterins may shuttle into cells via specific transporters³¹. It remains to be fully determined whether the DHFR pathway itself becomes dysfunctional in cardiovascular disease states.

In summary, insufficiency of BH₄ (potentially as a result of oxidation or reduced biosynthesis) leads to NOS uncoupling and the subsequent generation of reactive oxygen species, which can further oxidise and limit BH₄ bioavailability. This may result in a vicious cycle of sustained NOS uncoupling, reduced NO bioavailability and enhanced oxidative stress, further potentiating vascular dysfunction. Thus, pharmacological interventions that enhance BH₄ bioavailability within endothelial cells hold significant therapeutic potential for the treatment of numerous cardiovascular disorders.

4. BH₄ and phenylketonurea (PKU)

BH₄ was first identified as a cofactor for the aromatic amino acid hydroxylases (AAAH) and was shown to be necessary for the metabolism of phenylalanine, tyrosine and tryptophan^{1, 2, 32} and consequently the eventual biosynthesis of noradrenaline, dopamine and 5-hydroxytryptamine. There are a number of neurological disorders in humans that are related to abnormal BH₄ bioavailability and metabolism³³⁻³⁸. Of these, phenylketonurea (PKU) has been especially well characterised. Mutations in the phenylalanine hydroxylase (PAH) gene can lead to protein misfolding with loss of function and lead to the development of PKU. PKU is characterised by elevated circulated phenylalanine (hyperphenylalaninaemia) which can lead to impaired brain development and significant mental retardation during early life, and is the most common inborn error of amino acid metabolism in European descended populations³⁹. A strict phenylalanine (L-Phe) restricted diet (often with poor patient compliance) was for many years the only strategy implemented to control circulating L-Phe levels in PKU patients.

The clinical importance of BH₄ was first highlighted following the identification of atypical variants of hyperphenylalaninaemia who displayed neurological degeneration despite phenylalanine restriction^{36, 37}. Fortunately, research efforts focused on understanding whether pharmacological BH₄ supplementation could be used to treat PKU patients, led to the clinical development of sapropterin

dihydrochloride (Kuvan), a synthetic oral BH₄ supplement which has been successfully employed to increase dietary L-Phe tolerance and maintain blood L-Phe levels within an acceptable range, in a subset of hyperphenylalaninaemic patients (termed BH₄ responsive)⁴⁰⁻⁴³.

5. Regulation of nitric oxide bioavailability

Nitric oxide (NO) orchestrates a variety of important biological effects throughout the body, given the widespread distribution of the three NOS isoforms. These diverse biological effects include long term potentiation and memory formation, smooth muscle vasodilatation, inhibition of platelet aggregation and host defence – forming part of the inflammatory response to a microbial infection⁴⁴⁻⁴⁷. Given the diverse and profound effects of NO on various target tissues, there has been a great deal of interest in pharmacologically modulating NO bioavailability.

Following the discovery of endothelium derived relaxing factor and its subsequent identification as NO^{46,48} it has become well recognised that impaired vascular NO signalling contributes to the phenomenon of ‘endothelial dysfunction’, a hallmark feature of numerous cardiovascular diseases⁴⁹⁻⁵¹. NO supplementation using agents such as organic nitrates (e.g. glyceryl trinitrate and isosorbide mononitrate) for the treatment of coronary artery disease, or inhaled NO gas for the treatment of pulmonary hypertension in neonates, have been employed clinically for many years. Unfortunately, the prolonged use of these agents is often limited by the development of tolerance and potentially fatal rebound effects following withdrawal (inhaled NO)⁵²⁻⁵⁵.

Similarly, the inhibition of NOS for the treatment of refractory hypotension in septic shock patients showed initial benefits on hemodynamic responses, but overall resulted in an increased mortality rate, indicating the complexities of non selectively inhibiting all NOS isoforms^{56, 57}.

The difficulties associated with regulating vascular NO through the use of direct NO donors/NOS inhibitors, naturally led to investigations of endogenous NOS regulatory mechanisms, as an alternative method to control NO bioavailability. Such investigations have primarily studied interventions that can enhance vascular NO levels for the treatment of endothelial dysfunction and include enhancing L-arginine substrate bioavailability^{58, 59} and introducing antioxidants to limit the destruction of NO by reactive oxidant species^{60, 61}. Unfortunately, studies investigating the chronic administration of these agents suggests that such interventions lack clear efficacy and in some cases

worsen outcome, although it should be noted that there are inherent complexities with the design of these types of clinical trial ⁶²⁻⁶⁶.

Another possible target for regulating NO levels is the enzyme dimethylarginine dimethylaminohydrolase (DDAH). DDAH metabolises the endogenously produced NOS inhibitors, asymmetric dimethylarginine (ADMA) and L-N^G monomethyl-L-arginine (L-NMMA). However, to date only selective inhibitors of DDAH (which lead to an increase in ADMA) have been developed, suggesting that DDAH may be a more tractable target for diseases characterised by elevated NO such as inflammation and septic shock ⁶⁷⁻⁷⁰. Pharmacological DDAH activators may however, be successfully developed in the future as a method to reduce endogenous ADMA/L-NMMA and enhance vascular NO bioavailability within the cardiovascular system.

6. Regulation of BH₄ and vascular function

Intensive investigation over recent years has focused on understanding whether increasing BH₄ levels may also elicit therapeutic benefits for the treatment of cardiovascular disorders underpinned by endothelial dysfunction. Numerous rodent and clinical studies investigating genetic (GCH1 gene manipulation or human polymorphisms) have shown that loss of GCH1 activity exacerbates vascular dysfunction whilst over expression is protective, as described within section 7.1. Similarly animal studies and small scale acute clinical studies using pharmacologically supplemented BH₄, have demonstrated a correlation between enhanced BH₄ levels and improved vascular function ⁷¹⁻⁹⁹ and Tables 1 and 2. The chief limitation of these clinical studies, was the high doses of BH₄ administered 50-100 µM compared to physiological plasma levels of 10–50 nM ¹⁰⁰ which may have elicited NOS independent or other non specific effects ^{96, 101, 102}. Furthermore, only the acute vascular effects of BH₄ were assessed in these clinical studies and BH₄ was typically delivered via an intracoronary/intra arterial infusion, which is unrepresentative of a suitable route of administration for chronic disease management.

Clinical trials investigating oral BH₄ supplementation have shown varied efficacy in numerous disorders with an apparent lack of efficacy in diseases such as hypertension and coronary artery disease ¹⁰³⁻¹¹⁰ and Table 3. These findings may be explained by either rapid clearance of BH₄ after oral administration and/or enhanced oxidation following adsorption, with a consequent decrease in the vascular BH₄:BH₂ ratio, despite a clear elevation of BH₄ in the plasma pool ¹⁰³. Indeed, co-administration with ascorbate has been shown to enhance BH₄ bioavailability and in certain cases

improve vascular function, possibly through chemical stabilisation and increased regeneration of BH_3^+ to BH_4 ^{29, 106, 108, 111, 112}. However, studies in larger cohorts of patients would be required to determine whether this dual (BH_4 plus antioxidant) intervention would be efficacious on a chronic basis.

The cellular deposition of BH_4 after administration appears to be cell type dependent and either involves direct uptake of BH_4 or initial oxidation to BH_2 and subsequent reduction back to BH_4 by dihydrofolate reductase (DHFR) via the salvage pathway³⁰. An emerging literature indicates that DHFR also plays an important role in the maintenance of cellular BH_4 levels and NOS functionality. Enhanced hydrogen peroxide production arising from angiotensin II treatment reduces DHFR expression, siRNA knockdown of DHFR exacerbates NOS uncoupling and DHFR over expression elicits a restorative effect¹¹³⁻¹¹⁶. These studies suggest that DHFR may itself represent a therapeutic target for regulating vascular BH_4 levels and NOS functionality.

Thus, whilst the evidence clearly suggests that enhancing BH_4 within endothelial cells is beneficial, these recent clinical trials suggest that there are limitations to achieving this pharmacologically. The vascular effects following oral administration of BH_4 appear complex and dose dependent^{87, 103}. The ratio of BH_4 : BH_2 achieved within vascular endothelial cells may influence outcome and oral BH_4 supplementation could counter-intuitively elicit harmful effects through enhanced prevalence of the BH_2 species^{87, 103}. A detailed understanding of both the endogenous regulation of BH_4 in normal physiology and pathophysiology, its cellular uptake/recycling and the fate of orally administered BH_4 , appears necessary in order to develop safe, rational BH_4 modifying strategies for the treatment of endothelial dysfunction¹¹⁷.

Treatment	Cardiovascular effect	Species	Reference
BH ₄	augmented relaxation induced by acetylcholine in diabetic aortic rings	Rats	82
BH ₄	restoration of eNOS function and reduced vascular oxidative stress in insulin-resistant rats	Rats	83
BH ₄	Improves endothelial function and prevents the development of hypertension in SHR	Rats	84
Sepiapterin	improved endothelium-dependent vasodilatation in aortas from apoE ^{-/-} mice	Mice	85
BH ₄	Improved contractile and metabolic abnormalities in reperfused hearts	Rats	86
BH ₄	Improves endothelial dysfunction and vascular oxidative stress in microvessels of intrauterine undernourished rats	Rats	87
BH ₄	Prevented the development of hypertension and myocardial hypertrophy associated with long-term infusion of Ang II	Rats	88
Sepiapterin	Improved vascular relaxation in persistent pulmonary hypertension of newborn only when co-administered with superoxide dismutase (MnTMPyP)	Pig	77
BH ₄	Protection in myocardial ischaemia	Rats	81
BH ₄	Improved endothelial dysfunction, attenuates increased NADPH oxidase mRNA and inflammatory factors in the aortas of ApoE ^{-/-} mice	Mice	80
BH ₄	Inhibits hypoxic pulmonary vasoconstriction	Rats	79
BH ₄	Reduced atherosclerosis and in ApoE ^{-/-} mice	Mice	89
BH ₄	Protection following pressure-overload induced hypertrophy. Limited dose range	Mice	90

Table 1 Effects of pharmacological BH₄ administration in animal studies

Disease	Administration	Patient number	Outcome	Reference
Hypercholesterolemia	6R-BH ₄ (Alexis Corp.) 10, 100, 500, 1000 µg/min for 5 min	13	Restores endothelial dysfunction	91
Diabetes (type II)	6R-BH ₄ (Schrieks) intra-arterial infusion 500 µg/min.	23	Improves endothelium dependent vasodilatation	75
Chronic smoking	6R-BH ₄ (Schrieks) 500 µg/min	16	Improves endothelial function	102
Coronary heart disease	6R-BH ₄ (Alexis Corp.) intracoronary infusion 10 ⁻² M/min for 2 min	19	Prevents endothelial dysfunction	92
Hypertension	6R-BH ₄ (Sigma) 500 mg/min	16	Augments endothelium dependent vasodilatation in normotensive and hypertensive patients	93
Hypercholesterolemia	6R-BH ₄ (Sigma) Intracoronary 1mg/min	18	Improves coronary endothelial function	74
Vasospastic angina (VA)	6R-BH ₄ (Sigma) Intracoronary 1mg/min; 2 min	28	Improves coronary endothelial function but does not prevent coronary spasm in VA patients	94
Coronary artery disease	6R-BH ₄ 4 mg/min	15	Improves endothelium-dependent vasodilatation	78
Diabetes (type II)	6R-BH ₄ (Schrieks) intra-arterial infusion 500 µg/min	32	Increases insulin sensitivity but does not improve endothelial function	101
Hypercholesterolemia	6R-BH ₄ (Schrieks) 10 mg/kg 30 min i.v. infusion	19	Improves dysfunction of coronary microcirculation in hypercholesterolaemic patients	95
Endotoxin-induced endothelial dysfunction	6R-BH ₄ (Cinalfa) 500 µg/min for 47 min	8	Restores impaired endothelial function	96
Vascular aging	6R-BH ₄ (Schrieks) 10 mg/kg once	31	Improves endothelium dependent dilation	97
Vascular aging	6R-BH ₄ (Sigma) 500 mg/min	37	Prevents endothelial dysfunction	98
Ischemia reperfusion injury	6S and 6R-BH ₄ and NH ₄ (Schrieks) 500 µg/minH ₄	48	Both 6S and 6R BH ₄ improve endothelial function	99
Atherosclerosis	6R-BH ₄ (Cinalfa) intracoronary infusion 500 µg/min	57	Does not improve endothelial function	100

Table 2. Acute effects of BH₄ supplementation in human cardiovascular disease

Disease	Administration	Patient number	Outcome	Reference
Chronic smoking	2 mg/kg Sapropterin hydrochloride (single oral dose, measurements taken 3 and 24hr after admin) Biopten.	17	Improved vascular NO bioactivity-increased endothelium-dependent vasodilatation	110
Hypertension	1, 5 or 10 mg/kg/day of BH ₄ for 8 wks Schircks laboratory (BH ₄ preparations compounded with an equivalent amount of Vit C).	8 16	Reduced systolic pressure and MAP and improvement of endothelial function at higher doses	109
Hypercholesterolemia (LDL>4.5 mmol/L)	400 mg of BH ₄ twice daily over 4 wks. Schircks laboratory	22	Reversal of endothelial dysfunction and oxidative stress	111
Pulmonary arterial hypertension (Safety study)	2.5 mg/kg to 20mg/kg of Sapropterin dihydrochloride over 8 wks. Biomarin	18	Safety study revealed improvement in 6-minute walk distance Efficacy trial ongoing	112
Hypertension	5mg/kg of oral Sapropterin dihydrochloride twice daily for 8 wks. Biomarin	84	No significant effect on systolic blood pressure	NCT00325962 see 108
Endothelial dysfunction	5mg/kg of oral Sapropterin dihydrochloride twice daily for 2 wks. Biomarin	52	No significant difference	NCT00532844 see 108
Sickle cell disease	Sapropterin dihydrochloride twice daily, dose escalation (every 4 weeks) 2.5, 5, 10 mg/kg/day, and 20 mg/kg/day for 16 wks. Biomarin	40	Improvement in endothelial function	NCT00445978 see 108
Peripheral arterial disease	400 mg of oral Sapropterin dihydrochloride twice daily over 24 weeks. Biomarin	190	No significant difference	NCT00403494 see 108
Endothelial dysfunction Estrogen-deficiency	BH ₄ 10mg/kg (single oral dose, measurements taken 3 hrs after admin) Schircks laboratory	33	Increased endothelial dependent vasodilatation in post menopausal women	113
Coronary artery disease	400 or 700mg/day of Sapropterin dihydrochloride for 2-6 weeks. Biomarin	49	No significant difference	106

Table 3. Oral BH₄ supplementation in human cardiovascular disease

In contrast, strategies that attenuate the pathophysiological rise observed in BH₄ under proinflammatory conditions, may be of benefit in the management of conditions such as pain and septic shock¹¹⁸⁻¹²². Such conditions are underpinned by enhanced and sustained over production of NO derived from newly transcribed inducible NOS (iNOS) or, in the case of pain, additional increases in neurotransmitters such as noradrenaline, generated by AAAH. Understandably, caution must be exercised with any treatment strategies that directly limit BH₄ bioavailability on a chronic basis, given the potentially detrimental impact on NO biology or aromatic amino acid metabolism.

It is important to note that a greater level of complexity arises with strategies that limit BH₄ bioavailability for NOS. Whilst limiting BH₄ may attenuate the extent of an inflammatory response, through minimising iNOS dimerisation and activity in vascular smooth muscle, it would be important to ensure adequate BH₄ bioavailability for eNOS at the level of the microcirculation. Microvascular blood flow has been shown to be compromised in patients with sepsis¹²³ and therapeutic strategies that improve microvascular perfusion have correlated with reduced multiple organ failure in septic patients¹²⁴. In these situations, supplementation of NO or BH₄ have been suggested to be a method to improve microcirculatory function in sepsis^{125, 126}. Clearly the timing of intervention is critical and a more complete understanding of the BH₄ and NO profiles in sepsis is required in order to develop timely strategies for the management of the vascular alterations that occur in septic shock patients.

6.1 Other mechanism of action for BH₄

Besides the clear cofactor roles of BH₄ for AAAH, GEMO and NOS, a number of other roles of BH₄ have been identified. It is clear that BH₄ can behave as a direct antioxidant reacting with both superoxide¹²⁷ and more readily with peroxynitrite (ONOO⁻)^{27, 82}. Indeed the rate constant for the reaction between BH₄ and ONOO⁻ is several fold higher than the reactions for other known antioxidant systems including ascorbate, glutathione or thiol groups, and likely explains the primary antioxidant mechanism of BH₄²⁷.

BH₄ can react with molecular oxygen leading to the production of hydrogen peroxide which has been suggested to be an endothelium derived hyperpolarisation factor (EDHF)^{128, 129}. Supplementation of BH₄ to iliac arteries modulates arterial function by reducing oxidant stress and enhancing gap junctional communication and electrotonic signalling mediated by EDHF, independent of NO¹³⁰.

7. GCH1 manipulation and BH₄ regulation

One possible method of circumventing the potential problems associated with direct oral BH₄ administration would be to regulate BH₄ bioavailability intracellularly, by pharmacologically targeting enzymes involved in BH₄ biosynthesis or recycling. GCH1 performs the first and, under most circumstances, rate limiting step in BH₄ biosynthesis. Thus, small molecules that enhance GCH1 activity would increase BH₄ levels and eNOS derived NO within vascular cells for the treatment of endothelial dysfunction; whilst strategies that attenuate the inflammation induced rise in GCH1 activity could limit the bioavailable BH₄ for iNOS, as a means to reduce pathophysiological inflammation. The remainder of this article will focus on the evidence that supports the pharmacological modulation of GCH1 as a tractable target for both enhancing and inhibiting BH₄ bioavailability.

7.1 Genetic modification of GCH1

The availability of genetically modified mice has greatly contributed to our understanding of BH₄ biology in the cardiovascular system. Ubiquitous knockout of GCH1 is lethal *in utero* but inducible or conditional knockout of GCH1 may be feasible. Reduced GCH1, activity as observed in the Hph-1 mouse (generated by chemical mutagenesis)¹³¹, results in reduced BH₄ levels, NOS activity and mice exhibit a pulmonary hypertensive phenotype^{73, 132}. Conversely, endothelial cell targeted over

expression of GCH1 in mice elevates BH₄ levels, NOS activity and NO levels and mice display resistance to DOCA-salt induced systemic hypertension, hypoxia induced pulmonary hypertension and exhibit reduced atherosclerosis and endothelial dysfunction when crossed with Apo E mice^{73, 133, 134}. Following transluminal wire injury, GCH1 over expressing mice also display reduced neointima formation¹³⁵. Similarly adenoviral GCH1 gene transfer into endothelial cells enhances NO production and eNOS dimerisation and improves vascular function^{136 137} whilst siRNA induced knockdown elevates blood pressure in mice¹³⁸.

There are also a few, albeit small scale, studies in humans indicating that GCH1 polymorphisms result in a loss of function phenotype with concomitant detrimental effects on vascular function¹³⁹⁻¹⁴². In summary, loss of function of GCH1 results in predisposition to cardiovascular disease whilst over expression appears protective. These effects of experimental gene manipulation or existing human polymorphisms appear to be related to BH₄ bioavailability and NOS functionality.

7.2 Physiological and pharmacological modifiers of GCH1

There are a number of agents that can stimulate BH₄ production, many of which achieve this via increasing the expression or activity of GCH1. Up regulation of GCH1 has been reported at the level of transcription and translation by hormones including insulin¹⁴³ and oestrogen¹⁴⁴, physiological stimuli such as shear stress¹⁴⁵ and pharmacological agents including statins¹⁴⁶. These agents are known to elicit vascular protective effects and may thus achieve this, in part, through enhanced BH₄ bioavailability for NOS. Indeed, these studies support the observed protective effects of BH₄ supplementation in situations where such endogenous mechanisms have become dysfunctional^{72,}

110

Similarly in a pathological setting, proinflammatory cytokines have been shown to upregulate GCH1 and BH₄ levels¹⁴⁷⁻¹⁴⁹, whilst anti-inflammatory cytokines such as IL-4 and IL-10 and glucocorticoids have been shown to reverse this rise in BH₄^{150 151}. Proinflammatory cytokines are known to contribute to an inflammatory response by transcribing iNOS and enhancing reactive oxygen species generation and the generation of micromolar levels of NO, which have both protective antimicrobial and deleterious inflammatory effects. Indeed, aberrant iNOS mediated vascular NO production is also known to acutely contribute to the circulatory collapse observed in septic shock, and studies have shown that inhibition of GCH1 or antagonism of BH₄ binding to NOS, elicits protective effects in animal models of sepsis^{119, 120, 152}.

8.0 Pharmacological enhancers and inhibitors of BH₄ bioavailability

As described in section 4.0, a stable preparation of BH₄ (sapropterin dihydrochloride) has been granted FDA and EMEA approval as a means to regulate blood phenylalanine levels in a subset of hyperphenylalaninaemic patients. This compound is currently undergoing clinical investigation in a number of cardiovascular diseases although, unfortunately, initial results suggest sapropterin dihydrochloride lacks efficacy (Table 3).

Sepiapterin, a precursor which is converted to BH₄ via the salvage pathway (dihydrofolate reductase) (Fig. 1), is used experimentally to enhance BH₄ levels and has been shown to elicit a restorative effect of endothelial function in a number of cardiovascular disease models^{74, 82, 153}. However at high concentrations, sepiapterin may lead to an accumulation of 7,8-BH₂ which in turn may lead to NOS uncoupling and paradoxically elicit detrimental effects¹⁵⁴.

The B vitamin, folic acid has also been shown to elicit beneficial cardiovascular effects by both lowering homocysteine levels and through antioxidant effects which are likely mediated by its circulating reduced biologically active form, 5-methyltetrahydrofolate (5-MTHF). 5-MTHF administration restores BH₄ bioavailability, eNOS activity and endothelial function in human tissue^{155, 156}. These studies provide further evidence that the oxidative inactivation of BH₄ underlies numerous cardiovascular pathologies and that strategies limiting BH₄ oxidation, hold therapeutic promise. Finally, stable compounds that can directly activate NOS via the pterin binding site, have been developed. A stable analogue of BH₄ (6-acetyl-7,7-dimethyl-7,8-dihydropterin or ADDP) has been shown to substitute for BH₄ when the pterin binding site on NOS is unoccupied, eliciting beneficial effects on pulmonary vascular function^{157, 158}.

Pharmacological inhibitors which block the BH₄ biosynthetic or recycling pathways include the prototypic GCH1 inhibitor 2,4-diamino-6-hydroxypyrimidine (DAHP)^{83, 119, 120, 159-161}, and guanine mimetics including 8-azaguanine and 8-mercaptoguanine¹⁶²; methotrexate, an inhibitor dihydrofolate reductase^{30, 116}; and N-acetyl-serotonin which can inhibit sepiapterin reductase activity¹⁶³⁻¹⁶⁵.

Interestingly, some reagents that reduce BH₄ bioavailability or BH₄ binding to NOS, have demonstrated selectivity for iNOS functionality/expression^{164, 166}. Indeed, of the three NOS isoforms, iNOS dimer stability is especially sensitive to BH₄ levels¹⁶⁷. Thus small molecules that attenuate the

cytokine induced rise in BH₄ (normally necessary to support the stabilisation and activity of newly formed iNOS) may selectively inhibit iNOS function, potentially by destabilising/preventing dimer formation, whilst sparing eNOS mediated NO production.

9.0 GCH1 protein interactions

A number of GCH1 interacting proteins have been identified through yeast two hybrid and immunoprecipitation assays in tissues, some of which appear to be organ specific interactions ^{7, 168}. Certain proteins such as tyrosine hydroxylase in drosophila ¹⁶⁹, Heat shock protein 90 (Hsp90) related proteins and GCH1 feedback regulatory protein (discussed later) ^{7, 168} can be intuitively linked to the role of GCH1 and BH₄ in AAAH and NOS functionality. Hsp90 is an essential component of a chaperone complex that associates with eNOS and has been shown to be a dynamic regulator of eNOS activity in endothelial cells ¹⁷⁰. Interestingly GCH1 associates with the activator of Heat Shock 90 kDa Protein (Aha1) suggesting that this may be a mechanism whereby GCH1 may be recruited into endothelial cells to regulate BH₄ bioavailability for eNOS ⁷. Furthermore, the functional significance of the associations between GCH1, Hsp90 and the C-terminus of Hsp70-interacting protein (CHIP), have recently been demonstrated in a model of congenital heart disease and increased pulmonary blood flow (shunt lambs) where NO signalling is diminished in the pulmonary vasculature ¹⁷¹.

Other interacting proteins such as rabphilin-3A ¹⁷², the mitochondrial protein very long-chain specific acyl-CoA dehydrogenase (VLCAD) and eukaryotic translation initiation factors including EIF3I indicate that GCH1 may regulate other physiological processes although these remain to be demonstrated in functional systems ¹⁶⁸.

10.0 Post translational modification of GCH1

In addition to the pharmacological and physiological GCH1 regulators, GCH1 activity has also been shown to be controlled post translationally by phosphorylation ^{145, 173, 174} and via a functional protein-protein interaction ¹⁷⁵.

10.1 GCH1 Phosphorylation

Protein phosphorylation has been shown to modulate GCH1 resulting in elevated activity and an increase in cellular BH₄ levels. Examination of the amino acid sequence of GCH1 reveals several conserved putative phosphorylation motifs for casein kinase II and protein kinase C.

Agents such as angiotensin II and platelet derived growth factor (PDGF-BB) have been shown to stimulate GCH1 phosphorylation in a protein kinase C dependent manner ¹⁷⁴. Of the numerous putative phosphorylation motifs on GCH1, serine 81 (within the human sequence) has been shown to be functionally important and regulated by laminar shear stress ¹⁴⁵. These data suggest that BH₄ bioavailability may be dynamically regulated endogenously via the phosphorylation of GCH1. It still remains to be determined whether the other GCH1 phosphorylation motifs are functionally important.

10.2 GCH1 feedback regulatory protein

In addition to phosphorylation, biochemical studies have demonstrated that GCH1 is also subject to allosteric feedback inhibition by BH₄ and feed forward activation by the essential amino acid L-phenylalanine (L-Phe). However, this effect is only seen when GCH1 is bound to GCH1 Feedback Regulatory Protein (GFRP) ¹⁷⁵.

A series of elegant studies by Maita *et al.*, solved the crystal structures of the rodent GCH1–GFRP complex (residues 48-241 of GCH1 and residues 1-84 of GFRP) identifying the binding sites and interacting residues for both BH₄ (BH₂ was used experimentally due to increased stability) and L-Phe binding within the GCH1–GFRP complex ^{176, 177}. Crystallisation of the complete GCH1 protein was not possible due to proteolytic cleavage at arginine residues occurring within the first 47 amino acids of the N-terminus. Whilst it was suggested that this N-terminal portion was unlikely to be involved in substrate binding or catalysis ¹⁷⁸, other studies have indicated that this N-terminal portion may indeed associate with GFRP and may further elicit regulatory effects on enzyme activity ^{7, 179}.

10.3 BH₄ mediated inhibition and L-Phe mediated activation of the GCH1–GFRP complex

When present in excess, ten molecules of BH₄ bind to the GCH1–GFRP complex, within binding pockets that are exclusively located on GCH1 ¹⁷⁶. This binding induces conformational changes within the active site (in particular residues Phe-113 and Glu-115) potentially leading to incorrect positioning of the substrate GTP, reducing the V_{max} of the enzyme and thus reducing GCH1 activity.

Conversely, inhibition of GCH1 activity can be reversed by ten molecules of L-Phe, which bind exclusively within pockets located on GFRP and can stimulate enzyme activity in the presence of sub saturating GTP concentrations ¹⁷⁷. Thus L-Phe changes the protein complex conformation back to an active state and enhances BH₄ biosynthesis ^{162, 175, 177, 180}. Biopterin or L-Phe binding appear to enhance the association of GFRP with GCH1 by occupying the spaces at the interfaces thereby increasing the surface contact area between the two proteins.

The interaction of GCH1 with GFRP therefore renders GCH1 sensitive to changes in prevailing BH₄ and L-Phe concentrations. Fluctuations in circulating L-Phe, resulting from altered dietary intake, are therefore kept within a physiological range through the feed forward activation of BH₄ biosynthesis which in turn is a necessary cofactor for the hydroxylation reaction mediated by PAH^{1, 175}. Similarly, BH₄ levels are kept within an appropriate physiological range through feedback inhibition of GCH1¹⁷⁵.

Despite advances in our understanding of the physical interactions of GCH1 and GFRP^{7, 176, 177, 180}, the functional significance of the GCH1–GFRP interactions *in vivo*, has yet to be fully elucidated. However, evidence has demonstrated that these proteins do indeed interact *in vivo*. Firstly, an oral challenge of L-Phe in humans elicits an increase in plasma biopterin (a measurable correlate of plasma BH₄) and a rise in plasma and tissue BH₄ in mice (Starr and Nandi, unpublished), indicating that L-Phe stimulates GCH1 activity *in vivo*^{181, 182}. Secondly, administration of L-Phe increases endothelium-dependent relaxation and attenuates hypertension in rats made hypertensive by GCH1 inhibition¹⁸³. Finally, human epidermal melanocytes and keratinocytes have the capacity to regulate *de novo* BH₄ synthesis via a GCH1–GFRP axis, suggesting that the same regulatory axis likely exists in other cell types which co-express these two proteins¹⁸⁴.

Post translational regulation of GFRP has also been reported *in vitro*. Whilst proinflammatory cytokines up regulate GCH1, BH₄ levels and iNOS activity, a concurrent down regulation of GFRP expression has been reported^{185, 186}. It has been postulated that this combination of increased GCH1 and decreased GFRP may render GCH1 insensitive to feedback inhibition by the generated BH₄. This in turn would provide a continuous supply of BH₄ for the newly formed iNOS sustaining a high NO output. In contrast, under healthy naïve conditions, cellular BH₄ levels are likely to exist in sufficiently high concentrations and be tightly bound to eNOS. Thus, any changes in GFRP expression would be unlikely to alter eNOS functionality.

In support of this, we and others have previously demonstrated that over expression of GFRP in endothelial cells did not affect basal BH₄ and eNOS mediated NO production^{187, 188} but following proinflammatory stimulation attenuated the rise in BH₄ and consequently dampened iNOS mediated NO production¹⁸⁸. Therefore the relative ratio of GCH1:GFRP would likely influence the frequency of interaction between the two proteins and hence impact on the extent of feedback inhibition/feed forward activation elicited by BH₄ and L-Phe. This would subsequently determine the amount of bioavailable BH₄ and in turn NOS functionality. Whether the ratio of these two proteins is regulated and altered during pathophysiology, remains to be investigated.

In addition to proinflammatory stimuli, laminar shear stress appears to regulate the GCH1-GFRP complex. Laminar shear – a physical stimulus which is known to elicit vascular protective effects (as opposed to oscillatory shear), has been shown to phosphorylate GCH1 (Ser-81) leading to a significant increase in BH₄ levels ¹⁴⁵. Interestingly, a recent study by the same group demonstrated siRNA mediated knockdown GFRP enhanced GCH1 phosphorylation and that laminar shear caused in a disassociation between GFRP and GCH1 ¹⁸⁹. This data provides further evidence that modification of GCH1-GFRP protein-protein interactions and associations may have the capacity to regulate BH₄ levels in pathophysiology.

10.4 GCH1–GFRP protein-protein interactions – a druggable target?

The pharmacological modulation of the allosteric or physical interactions between GFRP–GCH1 offers an interesting therapeutic approach to control BH₄ bioavailability. This target is especially attractive as it provides the potential for both the activation and inhibition of GCH1, and hence the regulation of BH₄ in pathologies where NO is either limited (e.g. endothelial dysfunction) (Figure 2) or where NO contributes to pathophysiology (inflammatory pain and septic shock) (Figure 3).

Two GFRP pentamers form a sandwich like complex surrounding one GCH1 homodecamer ^{176, 177}. There are 10 identical BH₄ binding sites located on the GCH1 homodecamer and 5 identical L-Phe binding sites located on each GFRP pentamer. Both sets of ligand binding sites reside within the GCH1-GFRP interface ^{176, 177}.

It has been postulated that the phenylalanine-mediated binding of GFRP locks GCH1 into an active conformation such that effective substrate turnover occurs even at low GTP concentrations ¹⁷⁵. Small molecules that can mimic the conformational changes that occur in response to L-Phe binding, therefore have the potential to activate GCH1 and enhance intracellular BH₄ levels. Similarly, those that mimic the changes induced by BH₄ would have the opposite effect in situations where an over production of BH₄ and NO contributes to pathology. However, it has been argued that these binding sites may be poor drug targets because they exist on the interface of two large proteins with a large surface area ^{175, 190}.

Figure 2: Potential mechanisms to enhance BH₄ levels to treat endothelial dysfunction. Upper panel illustrates effects of insufficient BH₄. Lower panel illustrates methods to enhance BH₄ by 1) direct exogenous BH₄ administration; 2) Small molecule activators of GCH1-GFRP complex; 3) Enhancing DHFR mediated conversion of BH₂ to BH₄ 4) antioxidant therapy

Interestingly, advances in the understanding of protein-protein interaction biology^{191, 192} have suggested that the presence of energetic 'hot spots' within protein-protein interfaces that may be amendable to pharmacological modification. Thus, a more detailed understanding of the two proteins and structural changes that occur in response to feedback inhibition elicited by BH₄ and feed forward activation elicited by L-Phe, may identify regions other than the known ligand binding sites, which could provide a starting point for rational drug design. Such small molecules could either mimic the changes induced by L-Phe or BH₄ or they could weaken or strengthen the physical interaction between the two proteins¹⁹³. Whether the GCH1–GFRP complex is amenable to this type of drug discovery remains to be determined, but a detailed understanding of the biophysical interactions between the two proteins in the presence of natural ligands, in normal physiology and pathophysiology certainly warrants investigation.

Figure 3. Mechanisms to regulate cellular BH₄ under proinflammatory conditions. Upper panel illustrates proinflammatory stimulation of BH₄ biosynthesis. Lower panel illustrates methods to regulate iNOS mediated NO production under inflammatory conditions: 1) Small molecule inhibitors of GCH1-GFRP; 2) Inhibitors of BH₄ binding to NOS

11.0 Conclusion

Elevating vascular BH₄ levels for the treatment of diseases characterised by endothelial dysfunction holds significant therapeutic potential based on in clinical and preclinical animal model data. Similarly attenuating the rise in BH₄ during inflammatory states could be used to treat the circulatory collapse observed in septic shock patients. Oral administration of BH₄ may lack efficacy possibly as a result of oxidative inactivation during absorption.

Manipulation of BH₄ levels could be achieved at an intracellular level by targeting the activity of enzymes involved in its biosynthesis or recycling. In particular, the rate limiting enzyme, GCH1 can be dynamically regulated (i.e. both activated and inhibited) through allosteric interactions when bound to its regulatory protein, GFRP. This protein-protein complex may offer a novel mechanism to control BH₄ bioavailability at a cellular level for the treatment of a broad spectrum of diseases.

References

1. Kaufman S. The structure of the phenylalanine-hydroxylation cofactor. *Proc Natl Acad Sci U S A*. 1963;50:1085-1093
2. Nagatsu T, Levitt M, Udenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. *J Biol Chem*. 1964;239:2910-2917
3. Kwon NS, Nathan CF, Stuehr DJ. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. *J Biol Chem*. 1989;264:20496-20501
4. Tayeh MA, Marletta MA. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. *J Biol Chem*. 1989;264:19654-19658
5. Tietz A, Lindberg M, Kennedy EP. A new pteridine-requiring enzyme system for the oxidation of glyceryl ethers. *J Biol Chem*. 1964;239:4081-4090
6. Watschinger K, Keller MA, Golderer G, Hermann M, Maglione M, Sarg B, Lindner HH, Hermetter A, Werner-Felmayer G, Konrat R, Hulo N, Werner ER. Identification of the gene encoding alkylglycerol monooxygenase defines a third class of tetrahydrobiopterin-dependent enzymes. *Proc Natl Acad Sci U S A*. 2010;107:13672-13677
7. Swick L, Kapatos G. A yeast 2-hybrid analysis of human gtp cyclohydrolase i protein interactions. *J Neurochem*. 2006;97:1447-1455
8. Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. *Biochem J*. 2000;347 Pt 1:1-16
9. Werner-Felmayer G, Golderer G, Werner ER. Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. *Curr Drug Metab*. 2002;3:159-173
10. Werner ER, Blau N, Thony B. Tetrahydrobiopterin: Biochemistry and pathophysiology. *Biochem J*. 2011;438:397-414
11. Rebelo J, Auerbach G, Bader G, Bracher A, Nar H, Hosl C, Schramek N, Kaiser J, Bacher A, Huber R, Fischer M. Biosynthesis of pteridines. Reaction mechanism of gtp cyclohydrolase i. *J Mol Biol*. 2003;326:503-516
12. Baek KJ, Thiel BA, Lucas S, Stuehr DJ. Macrophage nitric oxide synthase subunits. Purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme. *J Biol Chem*. 1993;268:21120-21129
13. Bommel HM, Reif A, Frohlich LG, Frey A, Hofmann H, Marecak DM, Groehn V, Kotsonis P, La M, Koster S, Meinecke M, Bernhardt M, Weeger M, Ghisla S, Prestwich GD, Pfeleiderer W, Schmidt HH. Anti-pterins as tools to characterize the function of tetrahydrobiopterin in no synthase. *J Biol Chem*. 1998;273:33142-33149
14. Gorren AC, List BM, Schrammel A, Pitters E, Hemmens B, Werner ER, Schmidt K, Mayer B. Tetrahydrobiopterin-free neuronal nitric oxide synthase: Evidence for two identical highly anticooperative pteridine binding sites. *Biochemistry*. 1996;35:16735-16745
15. Klatt P, Schmidt K, Brunner F, Mayer B. Inhibitors of brain nitric oxide synthase. Binding kinetics, metabolism, and enzyme inactivation. *J Biol Chem*. 1994;269:1674-1680
16. Klatt P, Schmidt K, Lehner D, Glatter O, Bachinger HP, Mayer B. Structural analysis of porcine brain nitric oxide synthase reveals a role for tetrahydrobiopterin and L-arginine in the formation of an sds-resistant dimer. *EMBO J*. 1995;14:3687-3695
17. Presta A, Siddhanta U, Wu C, Sennequier N, Huang L, Abu-Soud HM, Erzurum S, Stuehr DJ. Comparative functioning of dihydro- and tetrahydropterins in supporting electron transfer, catalysis, and subunit dimerization in inducible nitric oxide synthase. *Biochemistry*. 1998;37:298-310
18. Wei CC, Wang ZQ, Tejero J, Yang YP, Hemann C, Hille R, Stuehr DJ. Catalytic reduction of a tetrahydrobiopterin radical within nitric-oxide synthase. *J Biol Chem*. 2008;283:11734-11742

19. Wei CC, Wang ZQ, Hemann C, Hille R, Stuehr DJ. A tetrahydrobiopterin radical forms and then becomes reduced during nomega-hydroxyarginine oxidation by nitric-oxide synthase. *J Biol Chem*. 2003;278:46668-46673
20. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: Structure, function and inhibition. *Biochem J*. 2001;357:593-615
21. Crane BR, Arvai AS, Ghosh DK, Wu C, Getzoff ED, Stuehr DJ, Tainer JA. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. *Science*. 1998;279:2121-2126
22. Gorren AC, Bec N, Schrammel A, Werner ER, Lange R, Mayer B. Low-temperature optical absorption spectra suggest a redox role for tetrahydrobiopterin in both steps of nitric oxide synthase catalysis. *Biochemistry*. 2000;39:11763-11770
23. Bec N, Gorren AC, Voelker C, Mayer B, Lange R. Reaction of neuronal nitric-oxide synthase with oxygen at low temperature. Evidence for reductive activation of the oxy-ferrous complex by tetrahydrobiopterin. *J Biol Chem*. 1998;273:13502-13508
24. Wei CC, Wang ZQ, Arvai AS, Hemann C, Hille R, Getzoff ED, Stuehr DJ. Structure of tetrahydrobiopterin tunes its electron transfer to the heme-dioxy intermediate in nitric oxide synthase. *Biochemistry*. 2003;42:1969-1977
25. Stuehr DJ, Kwon NS, Nathan CF, Griffith OW, Feldman PL, Wiseman J. N omega-hydroxy-l-arginine is an intermediate in the biosynthesis of nitric oxide from l-arginine. *J Biol Chem*. 1991;266:6259-6263
26. Schmidt PP, Lange R, Gorren AC, Werner ER, Mayer B, Andersson KK. Formation of a protonated trihydrobiopterin radical cation in the first reaction cycle of neuronal and endothelial nitric oxide synthase detected by electron paramagnetic resonance spectroscopy. *J Biol Inorg Chem*. 2001;6:151-158
27. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: Implications for uncoupling endothelial nitric-oxide synthase. *J Biol Chem*. 2003;278:22546-22554
28. Crabtree MJ, Smith CL, Lam G, Goligorsky MS, Gross SS. Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in no vs. Superoxide production by enos. *Am J Physiol Heart Circ Physiol*. 2008;294:H1530-1540
29. Takeda M, Yamashita T, Shinohara M, Sasaki N, Takaya T, Nakajima K, Inoue N, Masano T, Tawa H, Satomi-Kobayashi S, Toh R, Sugiyama D, Nishimura K, Yokoyama M, Hirata K, Kawashima S. Plasma tetrahydrobiopterin/dihydrobiopterin ratio: A possible marker of endothelial dysfunction. *Circ J*. 2009;73:955-962
30. Sawabe K, Wakasugi KO, Hasegawa H. Tetrahydrobiopterin uptake in supplemental administration: Elevation of tissue tetrahydrobiopterin in mice following uptake of the exogenously oxidized product 7,8-dihydrobiopterin and subsequent reduction by an anti-folate-sensitive process. *J Pharmacol Sci*. 2004;96:124-133
31. Ohashi A, Sugawara Y, Mamada K, Harada Y, Sumi T, Anzai N, Aizawa S, Hasegawa H. Membrane transport of sepiapterin and dihydrobiopterin by equilibrative nucleoside transporters: A plausible gateway for the salvage pathway of tetrahydrobiopterin biosynthesis. *Mol Genet Metab*. 2011;102:18-28
32. Storm CB, Kaufman S. The effect of variation of cofactor and substrate structure on the action of phenylalanine hydroxylase. *Biochem Biophys Res Commun*. 1968;32:788-793
33. Longo N. Disorders of biopterin metabolism. *J Inher Metab Dis*. 2009;32:333-342
34. Niederwieser A, Blau N, Wang M, Joller P, Atares M, Cardesa-Garcia J. Gtp cyclohydrolase i deficiency, a new enzyme defect causing hyperphenylalaninemia with neopterin, biopterin, dopamine, and serotonin deficiencies and muscular hypotonia. *Eur J Pediatr*. 1984;141:208-214
35. Neville BG, Parascandolo R, Farrugia R, Felice A. Sepiapterin reductase deficiency: A congenital dopa-responsive motor and cognitive disorder. *Brain*. 2005;128:2291-2296

36. Bartholome K. Letter: A new molecular defect in phenylketonuria. *Lancet*. 1974;2:1580
37. Kaufman S, Berlow S, Summer GK, Milstien S, Schulman JD, Orloff S, Spielberg S, Pueschel S. Hyperphenylalaninemia due to a deficiency of biopterin. A variant form of phenylketonuria. *N Engl J Med*. 1978;299:673-679
38. Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M, Nomura Y, Endo K, Tanaka H, Tsuji S, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the gtp cyclohydrolase i gene. *Nat Genet*. 1994;8:236-242
39. Zschocke J. Phenylketonuria mutations in europe. *Hum Mutat*. 2003;21:345-356
40. Trefz FK, Burton BK, Longo N, Casanova MM, Gruskin DJ, Dorenbaum A, Kakkis ED, Crombez EA, Grange DK, Harmatz P, Lipson MH, Milanowski A, Randolph LM, Vockley J, Whitley CB, Wolff JA, Bebachuk J, Christ-Schmidt H, Hennermann JB. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: A phase iii, randomized, double-blind, placebo-controlled study. *J Pediatr*. 2009;154:700-707
41. Burton BK, Grange DK, Milanowski A, Vockley G, Feillet F, Crombez EA, Abadie V, Harding CO, Cederbaum S, Dobbelaere D, Smith A, Dorenbaum A. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6r-tetrahydrobiopterin): A phase ii, multicentre, open-label, screening study. *J Inherit Metab Dis*. 2007;30:700-707
42. Muntau AC, Roschinger W, Habich M, Demmelmair H, Hoffmann B, Sommerhoff CP, Roscher AA. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. *N Engl J Med*. 2002;347:2122-2132
43. Xia T, Gray DW, Shiman R. Regulation of rat liver phenylalanine hydroxylase. Iii. Control of catalysis by (6r)-tetrahydrobiopterin and phenylalanine. *J Biol Chem*. 1994;269:24657-24665
44. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. *Proc Natl Acad Sci U S A*. 1991;88:4651-4655
45. Bohme GA, Bon C, Lemaire M, Reibaud M, Piot O, Stutzmann JM, Doble A, Blanchard JC. Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats. *Proc Natl Acad Sci U S A*. 1993;90:9191-9194
46. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature*. 1980;288:373-376
47. Murray HW, Nathan CF. Macrophage microbicidal mechanisms in vivo: Reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral leishmania donovani. *J Exp Med*. 1999;189:741-746
48. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. *Nature*. 1987;327:524-526
49. Bhagat K, Hingorani A, Vallance P. Flow associated or flow mediated dilatation? More than just semantics. *Heart*. 1997;78:7-8
50. Loscalzo J. Endothelial injury, vasoconstriction, and its prevention. *Tex Heart Inst J*. 1995;22:180-184
51. Marshall JJ, Kontos HA. Endothelium-derived relaxing factors. A perspective from in vivo data. *Hypertension*. 1990;16:371-386
52. Kosmicki MA. Long-term use of short- and long-acting nitrates in stable angina pectoris. *Curr Clin Pharmacol*. 2009;4:132-141
53. Daiber A, Oelze M, Wenzel P, Wickramanayake JM, Schuhmacher S, Jansen T, Lackner KJ, Torzewski M, Munzel T. Nitrate tolerance as a model of vascular dysfunction: Roles for mitochondrial aldehyde dehydrogenase and mitochondrial oxidative stress. *Pharmacol Rep*. 2009;61:33-48
54. Lavoie A, Hall JB, Olson DM, Wylam ME. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. *Am J Respir Crit Care Med*. 1996;153:1985-1987

55. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, Chang CT. Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. *Pediatrics*. 1999;104:231-236
56. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546c88: Effect on survival in patients with septic shock. *Crit Care Med*. 2004;32:21-30
57. Watson D, Grover R, Anzueto A, Lorente J, Smithies M, Bellomo R, Guntupalli K, Grossman S, Donaldson J, Le Gall JR. Cardiovascular effects of the nitric oxide synthase inhibitor ng-methyl-L-arginine hydrochloride (546c88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). *Crit Care Med*. 2004;32:13-20
58. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. *J Clin Invest*. 1992;90:1168-1172
59. Lerman A, Burnett JC, Jr., Higano ST, McKinley LJ, Holmes DR, Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. *Circulation*. 1998;97:2123-2128
60. Tousoulis D, Xenakis C, Tentolouris C, Davies G, Antoniadis C, Crake T, Stefanadis C. Effects of vitamin c on intracoronary L-arginine dependent coronary vasodilatation in patients with stable angina. *Heart*. 2005;91:1319-1323
61. Hirooka Y, Eshima K, Setoguchi S, Kishi T, Egashira K, Takeshita A. Vitamin c improves attenuated angiotensin ii-induced endothelium-dependent vasodilation in human forearm vessels. *Hypertens Res*. 2003;26:953-959
62. Sun T, Zhou WB, Luo XP, Tang YL, Shi HM. Oral L-arginine supplementation in acute myocardial infarction therapy: A meta-analysis of randomized controlled trials. *Clin Cardiol*. 2009;32:649-652
63. Ness A, Egger M, Smith GD. Role of antioxidant vitamins in prevention of cardiovascular diseases. Meta-analysis seems to exclude benefit of vitamin c supplementation. *BMJ*. 1999;319:577
64. Bleys J, Miller ER, 3rd, Pastor-Barriuso R, Appel LJ, Guallar E. Vitamin-mineral supplementation and the progression of atherosclerosis: A meta-analysis of randomized controlled trials. *Am J Clin Nutr*. 2006;84:880-887; quiz 954-885
65. Chen H, Karne RJ, Hall G, Campia U, Panza JA, Cannon RO, 3rd, Wang Y, Katz A, Levine M, Quon MJ. High-dose oral vitamin c partially replenishes vitamin c levels in patients with type 2 diabetes and low vitamin c levels but does not improve endothelial dysfunction or insulin resistance. *Am J Physiol Heart Circ Physiol*. 2006;290:H137-145
66. Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP. L-arginine supplementation in peripheral arterial disease: No benefit and possible harm. *Circulation*. 2007;116:188-195
67. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A, Stidwill R, McDonald NQ, Vallance P. Disruption of methylarginine metabolism impairs vascular homeostasis. *Nat Med*. 2007;13:198-203
68. Rossiter S, Smith CL, Malaki M, Nandi M, Gill H, Leiper JM, Vallance P, Selwood DL. Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase. *J Med Chem*. 2005;48:4670-4678
69. Leiper J, Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. *Nat Rev Drug Discov*. 2011;10:277-291
70. Nandi M, Kelly P, Torondel B, Wang Z, Starr A, Ma Y, Cunningham P, Stidwill R, Leiper J. Genetic and pharmacological inhibition of dimethylarginine dimethylaminohydrolase 1 is protective in endotoxic shock. *Arterioscler Thromb Vasc Biol*. 2012

71. Fukuda Y, Teragawa H, Matsuda K, Yamagata T, Matsuura H, Chayama K. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. *Heart*. 2002;87:264-269
72. Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type ii diabetes mellitus. *Diabetologia*. 2000;43:1435-1438
73. Khoo JP, Zhao L, Alp NJ, Bendall JK, Nicoli T, Rockett K, Wilkins MR, Channon KM. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. *Circulation*. 2005;111:2126-2133
74. Nandi M, Leiper J, Arrighi F, Hislop A, Vallance P, Haworth S. Developmental regulation of gtp-ch1 in the porcine lung and its relationship to pulmonary vascular relaxation. *Pediatr Res*. 2006;59:767-772
75. Setoguchi S, Mohri M, Shimokawa H, Takeshita A. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. *J Am Coll Cardiol*. 2001;38:493-498
76. Francis BN, Wilkins MR, Zhao L. Tetrahydrobiopterin and the regulation of hypoxic pulmonary vasoconstriction. *Eur Respir J*. 2010;36:323-330
77. Hattori Y, Hattori S, Wang X, Satoh H, Nakanishi N, Kasai K. Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein e-knockout mice. *Arterioscler Thromb Vasc Biol*. 2007;27:865-870
78. Dumitrescu C, Biondi R, Xia Y, Cardounel AJ, Druhan LJ, Ambrosio G, Zweier JL. Myocardial ischemia results in tetrahydrobiopterin (bh4) oxidation with impaired endothelial function ameliorated by bh4. *Proc Natl Acad Sci U S A*. 2007;104:15081-15086
79. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. *J Cardiovasc Pharmacol*. 1997;29:8-15
80. Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H, Masada M, Toda N, Kikkawa R, Kashiwagi A. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. *Circ Res*. 2000;87:566-573
81. Hong HJ, Hsiao G, Cheng TH, Yen MH. Supplementation with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. *Hypertension*. 2001;38:1044-1048
82. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, Harrison DG. Endothelial regulation of vasomotion in apoe-deficient mice: Implications for interactions between peroxynitrite and tetrahydrobiopterin. *Circulation*. 2001;103:1282-1288
83. Yamashiro S, Noguchi K, Kuniyoshi Y, Koja K, Sakanashi M. Role of tetrahydrobiopterin on ischemia-reperfusion injury in isolated perfused rat hearts. *J Cardiovasc Surg (Torino)*. 2003;44:37-49
84. Franco Mdo C, Fortes ZB, Akamine EH, Kawamoto EM, Scavone C, de Britto LR, Muscara MN, Teixeira SA, Tostes RC, Carvalho MH, Nigro D. Tetrahydrobiopterin improves endothelial dysfunction and vascular oxidative stress in microvessels of intrauterine undernourished rats. *J Physiol*. 2004;558:239-248
85. Kase H, Hashikabe Y, Uchida K, Nakanishi N, Hattori Y. Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin ii-induced oxidative and nitrosative stress. *J Hypertens*. 2005;23:1375-1382
86. Schmidt TS, McNeill E, Douglas G, Crabtree MJ, Hale AB, Khoo J, O'Neill CA, Cheng A, Channon KM, Alp NJ. Tetrahydrobiopterin supplementation reduces atherosclerosis and vascular inflammation in apolipoprotein e-knockout mice. *Clin Sci (Lond)*. 2010;119:131-142

87. Moens AL, Ketner EA, Takimoto E, Schmidt TS, O'Neill CA, Wolin MS, Alp NJ, Channon KM, Kass DA. Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure. *J Mol Cell Cardiol.* 2011;51:564-569
88. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. *J Clin Invest.* 1997;99:41-46
89. Maier W, Cosentino F, Lutolf RB, Fleisch M, Seiler C, Hess OM, Meier B, Luscher TF. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. *J Cardiovasc Pharmacol.* 2000;35:173-178
90. Higashi Y, Sasaki S, Nakagawa K, Fukuda Y, Matsuura H, Oshima T, Chayama K. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. *Am J Hypertens.* 2002;15:326-332
91. Fukuda Y, Teragawa H, Matsuda K, Yamagata T, Matsuura H, Chayama K. Tetrahydrobiopterin improves coronary endothelial function, but does not prevent coronary spasm in patients with vasospastic angina. *Circ J.* 2002;66:58-62
92. Wyss CA, Koepfli P, Namdar M, Siegrist PT, Luscher TF, Camici PG, Kaufmann PA. Tetrahydrobiopterin restores impaired coronary microvascular dysfunction in hypercholesterolaemia. *Eur J Nucl Med Mol Imaging.* 2005;32:84-91
93. Mittermayer F, Pleiner J, Schaller G, Zorn S, Namiranian K, Kapiotis S, Bartel G, Wolfrum M, Brugel M, Thiery J, Macallister RJ, Wolzt M. Tetrahydrobiopterin corrects escherichia coli endotoxin-induced endothelial dysfunction. *Am J Physiol Heart Circ Physiol.* 2005;289:H1752-1757
94. Eskurza I, Myerburgh LA, Kahn ZD, Seals DR. Tetrahydrobiopterin augments endothelium-dependent dilatation in sedentary but not in habitually exercising older adults. *J Physiol.* 2005;568:1057-1065
95. Higashi Y, Sasaki S, Nakagawa K, Kimura M, Noma K, Hara K, Jitsuiki D, Goto C, Oshima T, Chayama K, Yoshizumi M. Tetrahydrobiopterin improves aging-related impairment of endothelium-dependent vasodilation through increase in nitric oxide production. *Atherosclerosis.* 2006;186:390-395
96. Mayahi L, Heales S, Owen D, Casas JP, Harris J, MacAllister RJ, Hingorani AD. (6r)-5,6,7,8-tetrahydro-l-biopterin and its stereoisomer prevent ischemia reperfusion injury in human forearm. *Arterioscler Thromb Vasc Biol.* 2007;27:1334-1339
97. Worthley MI, Kanani RS, Sun YH, Sun Y, Goodhart DM, Curtis MJ, Anderson TJ. Effects of tetrahydrobiopterin on coronary vascular reactivity in atherosclerotic human coronary arteries. *Cardiovasc Res.* 2007;76:539-546
98. Nystrom T, Nygren A, Sjöholm A. Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. *Am J Physiol Endocrinol Metab.* 2004;287:E919-925
99. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, Meinertz T, Munzel T. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : Evidence for a dysfunctional nitric oxide synthase. *Circ Res.* 2000;86:E36-41
100. Cunningham C, Channon KM. Tetrahydrobiopterin: Pleiotropic roles in cardiovascular pathophysiology. *Heart.* 2010;96:1872-1877
101. Vasquez-Vivar J, Martasek P, Whitsett J, Joseph J, Kalyanaraman B. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: An epr spin trapping study. *Biochem J.* 2002;362:733-739
102. Channon KM. Tetrahydrobiopterin: Regulator of endothelial nitric oxide synthase in vascular disease. *Trends Cardiovasc Med.* 2004;14:323-327
103. Cunningham C, Van Assche T, Shirodaria C, Kylintireas I, Lindsay AC, Lee JM, Antoniadou C, Margaritis M, Lee R, Cerrato R, Crabtree MJ, Francis JM, Sayeed R, Ratnatunga C, Pillai R,

- Choudhury RP, Neubauer S, Channon KM. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. *Circulation*. 2012;125:1356-1366
104. Katusic ZS, d'Uscio LV, Nath KA. Vascular protection by tetrahydrobiopterin: Progress and therapeutic prospects. *Trends Pharmacol Sci*. 2009;30:48-54
  105. Moens AL, Kietadisorn R, Lin JY, Kass D. Targeting endothelial and myocardial dysfunction with tetrahydrobiopterin. *J Mol Cell Cardiol*. 2011;51:559-563
  106. Porkert M, Sher S, Reddy U, Cheema F, Niessner C, Kolm P, Jones DP, Hooper C, Taylor WR, Harrison D, Quyyumi AA. Tetrahydrobiopterin: A novel antihypertensive therapy. *J Hum Hypertens*. 2008;22:401-407
  107. Ueda S, Matsuoka H, Miyazaki H, Usui M, Okuda S, Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. *J Am Coll Cardiol*. 2000;35:71-75
  108. Cosentino F, Hurlimann D, Delli Gatti C, Chenevard R, Blau N, Alp NJ, Channon KM, Eto M, Lerch P, Enseleit F, Ruschitzka F, Volpe M, Luscher TF, Noll G. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. *Heart*. 2008;94:487-492
  109. Robbins IM, Hemnes AR, Gibbs JS, Christman BW, Howard L, Meehan S, Cabrita I, Gonzalez R, Oyler T, Zhao L, Du RH, Mendes LA, Wilkins MR. Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. *Exp Lung Res*. 2011;37:26-34
  110. Moreau KL, Meditz A, Deane KD, Kohrt WM. Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. *Am J Physiol Heart Circ Physiol*. 2012;302:H1211-1218
  111. d'Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Long-term vitamin c treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. *Circ Res*. 2003;92:88-95
  112. Huang A, Vita JA, Venema RC, Keaney JF, Jr. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. *J Biol Chem*. 2000;275:17399-17406
  113. Seujsange Y, Eiam-Ong S, Tirawatnapong T. Role of angiotensin ii on dihydrofolate reductase, gtp-cyclohydrolase 1 and nitric oxide synthase expressions in renal ischemia-reperfusion. *Am J Nephrol*. 2008;28:692-700
  114. Chalupsky K, Cai H. Endothelial dihydrofolate reductase: Critical for nitric oxide bioavailability and role in angiotensin ii uncoupling of endothelial nitric oxide synthase. *Proc Natl Acad Sci U S A*. 2005;102:9056-9061
  115. Gao L, Chalupsky K, Stefani E, Cai H. Mechanistic insights into folic acid-dependent vascular protection: Dihydrofolate reductase (dhfr)-mediated reduction in oxidant stress in endothelial cells and angiotensin ii-infused mice: A novel hplc-based fluorescent assay for dhfr activity. *J Mol Cell Cardiol*. 2009;47:752-760
  116. Crabtree MJ, Hale AB, Channon KM. Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency. *Free Radic Biol Med*. 2011;50:1639-1646
  117. Fiege B, Ballhausen D, Kierat L, Leimbacher W, Goriounov D, Schircks B, Thony B, Blau N. Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. *Mol Genet Metab*. 2004;81:45-51
  118. Tegeder I, Costigan M, Griffin RS, Abele A, Belfer I, Schmidt H, Ehnert C, Nejim J, Marian C, Scholz J, Wu T, Allchorne A, Diatchenko L, Binshtok AM, Goldman D, Adolph J, Sama S, Atlas SJ, Carlezon WA, Parsegian A, Lotsch J, Fillingim RB, Maixner W, Geisslinger G, Max MB, Woolf CJ. Gtp cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. *Nat Med*. 2006;12:1269-1277

119. Bahrami S, Fitzal F, Peichl G, Gasser H, Fuerst W, Banerjee A, Strohmaier W, Redl H, Werner-Felmayer G, Werner ER. Protection against endotoxemia in rats by a novel tetrahydrobiopterin analogue. *Shock*. 2000;13:386-391
120. Li HY, Yao YM, Shi ZG, Dong N, Yu Y, Lu LR, Sheng ZY. Effect of 2,4-diamino-6-hydroxypyrimidine on postburn staphylococcus aureus sepsis in rats. *Crit Care Med*. 2002;30:2520-2527
121. Costigan M, Latremoliere A, Woolf CJ. Analgesia by inhibiting tetrahydrobiopterin synthesis. *Curr Opin Pharmacol*. 2012;12:92-99
122. Hoshiai K, Hattan N, Fukuyama N, Tadaki F, Hida M, Saito A, Nakanishi N, Hattori Y, Nakazawa H. Increased plasma tetrahydrobiopterin in septic shock is a possible therapeutic target. *Pathophysiology*. 2001;7:275-281
123. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. *Am J Respir Crit Care Med*. 2002;166:98-104
124. Trzeciak S, McCoy JV, Phillip Dellinger R, Arnold RC, Rizzuto M, Abate NL, Shapiro NI, Parrillo JE, Hollenberg SM. Early increases in microcirculatory perfusion during protocol-directed resuscitation are associated with reduced multi-organ failure at 24 h in patients with sepsis. *Intensive Care Med*. 2008;34:2210-2217
125. He X, Su F, Velissaris D, Salgado DR, Barros Dde S, Lorent S, Taccone FS, Vincent JL, De Backer D. Administration of tetrahydrobiopterin improves the microcirculation and outcome in an ovine model of septic shock*. *Crit Care Med*. 2012;40:2833-2840
126. Boerma EC, Koopmans M, Konijn A, Kaiferova K, Bakker AJ, van Roon EN, Buter H, Bruins N, Egbers PH, Gerritsen RT, Koetsier PM, Kingma WP, Kuiper MA, Ince C. Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: A double-blind randomized placebo controlled trial. *Crit Care Med*. 2010;38:93-100
127. Vasquez-Vivar J, Whitsett J, Martasek P, Hogg N, Kalyanaraman B. Reaction of tetrahydrobiopterin with superoxide: Epr-kinetic analysis and characterization of the pteridine radical. *Free Radic Biol Med*. 2001;31:975-985
128. Garry A, Edwards DH, Fallis IF, Jenkins RL, Griffith TM. Ascorbic acid and tetrahydrobiopterin potentiate the edhf phenomenon by generating hydrogen peroxide. *Cardiovasc Res*. 2009;84:218-226
129. Shimokawa H. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. *Pflugers Arch*. 2010;459:915-922
130. Griffith TM, Chaytor AT, Bakker LM, Edwards DH. 5-methyltetrahydrofolate and tetrahydrobiopterin can modulate electrotonically mediated endothelium-dependent vascular relaxation. *Proc Natl Acad Sci U S A*. 2005;102:7008-7013
131. McDonald JD, Bode VC. Hyperphenylalaninemia in the hph-1 mouse mutant. *Pediatr Res*. 1988;23:63-67
132. Nandi M, Miller A, Stidwill R, Jacques TS, Lam AA, Haworth S, Heales S, Vallance P. Pulmonary hypertension in a gtp-cyclohydrolase 1-deficient mouse. *Circulation*. 2005;111:2086-2090
133. Du YH, Guan YY, Alp NJ, Channon KM, Chen AF. Endothelium-specific gtp cyclohydrolase i overexpression attenuates blood pressure progression in salt-sensitive low-renin hypertension. *Circulation*. 2008;117:1045-1054
134. Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic gtp-cyclohydrolase i overexpression reduces endothelial dysfunction and atherosclerosis in apoe-knockout mice. *Arterioscler Thromb Vasc Biol*. 2004;24:445-450
135. Liao SJ, Lin L, Zeng JS, Huang RX, Channon KM, Chen AF. Endothelium-targeted transgenic gtp-cyclohydrolase i overexpression inhibits neointima formation in mouse carotid artery. *Clin Exp Pharmacol Physiol*. 2007;34:1260-1266

136. Cai S, Alp NJ, McDonald D, Smith I, Kay J, Canevari L, Heales S, Channon KM. Gtp cyclohydrolase i gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: Effects on nitric oxide synthase activity, protein levels and dimerisation. *Cardiovasc Res*. 2002;55:838-849
137. Meininger CJ, Cai S, Parker JL, Channon KM, Kelly KA, Becker EJ, Wood MK, Wade LA, Wu G. Gtp cyclohydrolase i gene transfer reverses tetrahydrobiopterin deficiency and increases nitric oxide synthesis in endothelial cells and isolated vessels from diabetic rats. *FASEB J*. 2004;18:1900-1902
138. Wang S, Xu J, Song P, Wu Y, Zhang J, Chul Choi H, Zou MH. Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. *Hypertension*. 2008;52:484-490
139. Antoniadou C, Shirodaria C, Van Assche T, Cunningham C, Tegeder I, Lotsch J, Guzik TJ, Leeson P, Diesch J, Tousoulis D, Stefanadis C, Costigan M, Woolf CJ, Alp NJ, Channon KM. Gch1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function. *J Am Coll Cardiol*. 2008;52:158-165
140. Zhang L, Rao F, Zhang K, Khandrika S, Das M, Vaingankar SM, Bao X, Rana BK, Smith DW, Wessel J, Salem RM, Rodriguez-Flores JL, Mahata SK, Schork NJ, Ziegler MG, O'Connor DT. Discovery of common human genetic variants of gtp cyclohydrolase 1 (gch1) governing nitric oxide, autonomic activity, and cardiovascular risk. *J Clin Invest*. 2007;117:2658-2671
141. Liao YF, Zeng TS, Chen LL, Li YM, Yu F, Hu LJ, Yue L. Association of a functional polymorphism (c59038t) in gtp cyclohydrolase 1 gene and type 2 diabetic macrovascular disease in the chinese population. *J Diabetes Complications*. 2010;24:313-319
142. Doebering A, Antoniadou C, Channon KM, Tegeder I, Lotsch J. Clinical genetics of functionally mild non-coding gtp cyclohydrolase 1 (gch1) polymorphisms modulating pain and cardiovascular risk. *Mutat Res*. 2008;659:195-201
143. Ishii M, Shimizu S, Nagai T, Shiota K, Kiuchi Y, Yamamoto T. Stimulation of tetrahydrobiopterin synthesis induced by insulin: Possible involvement of phosphatidylinositol 3-kinase. *Int J Biochem Cell Biol*. 2001;33:65-73
144. Sun X, Kumar S, Tian J, Black SM. Estradiol increases gtp cyclohydrolase expression via the nitric oxide mediated activation of camp response element binding protein. *Endocrinology*. 2009
145. Widder JD, Chen W, Li L, Dikalov S, Thony B, Hatakeyama K, Harrison DG. Regulation of tetrahydrobiopterin biosynthesis by shear stress. *Circ Res*. 2007;101:830-838
146. Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K. Hmg-coa reductase inhibitor increases gtp cyclohydrolase i mrna and tetrahydrobiopterin in vascular endothelial cells. *Arterioscler Thromb Vasc Biol*. 2003;23:176-182
147. Katusic ZS, Stelter A, Milstien S. Cytokines stimulate gtp cyclohydrolase i gene expression in cultured human umbilical vein endothelial cells. *Arterioscler Thromb Vasc Biol*. 1998;18:27-32
148. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Schmidt K, Weiss G, Wachter H. Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic gmp. *J Biol Chem*. 1993;268:1842-1846
149. Walter R, Linscheid P, Blau N, Kierat L, Schaffner A, Schoedon G. Induction of tetrahydrobiopterin synthesis in human umbilical vein smooth muscle cells by inflammatory stimuli. *Immunol Lett*. 1998;60:13-17
150. Schoedon G, Schneemann M, Blau N, Edgell CJ, Schaffner A. Modulation of human endothelial cell tetrahydrobiopterin synthesis by activating and deactivating cytokines: New perspectives on endothelium-derived relaxing factor. *Biochem Biophys Res Commun*. 1993;196:1343-1348

151. Simmons WW, Ungureanu-Longrois D, Smith GK, Smith TW, Kelly RA. Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and L-arginine transport. *J Biol Chem.* 1996;271:23928-23937
152. Werner ER, Werner-Felmayer G. Biopterin analogues: Novel nitric oxide synthase inhibitors with immunosuppressive action. *Curr Drug Metab.* 2002;3:119-121
153. Teng RJ, Du J, Xu H, Bakhutashvili I, Eis A, Shi Y, Pritchard KA, Jr., Konduri GG. Sepiapterin improves angiogenesis of pulmonary artery endothelial cells with in utero pulmonary hypertension by recoupling endothelial nitric oxide synthase. *Am J Physiol Lung Cell Mol Physiol.* 2011;301:L334-345
154. Vasquez-Vivar J, Duquaine D, Whitsett J, Kalyanaraman B, Rajagopalan S. Altered tetrahydrobiopterin metabolism in atherosclerosis: Implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. *Arterioscler Thromb Vasc Biol.* 2002;22:1655-1661
155. Moens AL, Vrints CJ, Claeys MJ, Timmermans JP, Champion HC, Kass DA. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. *Am J Physiol Heart Circ Physiol.* 2008;294:H1971-1977
156. Antoniadou C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R, Refsum H, Channon KM. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. *Circulation.* 2006;114:1193-1201
157. Suckling CJ, Gibson CL, Huggan JK, Morthala RR, Clarke B, Kununthur S, Wadsworth RM, Daff S, Papale D. 6-acetyl-7,7-dimethyl-5,6,7,8-tetrahydropterin is an activator of nitric oxide synthases. *Bioorg Med Chem Lett.* 2008;18:1563-1566
158. Kununthur SP, Milliken PH, Gibson CL, Suckling CJ, Wadsworth RM. Tetrahydrobiopterin analogues with no-dependent pulmonary vasodilator properties. *Eur J Pharmacol.* 2011;650:371-377
159. Kolinsky MA, Gross SS. The mechanism of potent gtp cyclohydrolase i inhibition by 2,4-diamino-6-hydroxypyrimidine: Requirement of the gtp cyclohydrolase i feedback regulatory protein. *J Biol Chem.* 2004;279:40677-40682
160. Cosentino F, Katusic ZS. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. *Circulation.* 1995;91:139-144
161. Mitchell BM, Dorrance AM, Webb RC. Gtp cyclohydrolase 1 inhibition attenuates vasodilation and increases blood pressure in rats. *Am J Physiol Heart Circ Physiol.* 2003;285:H2165-2170
162. Yoneyama T, Hatakeyama K. Ligand binding to the inhibitory and stimulatory gtp cyclohydrolase i/gtp cyclohydrolase i feedback regulatory protein complexes. *Protein Sci.* 2001;10:871-878
163. Milstien S, Kaufman S. Tetrahydro-sepiapterin is an intermediate in tetrahydrobiopterin biosynthesis. *Biochem Biophys Res Commun.* 1983;115:888-893
164. Schoedon G, Blau N, Schneemann M, Flury G, Schaffner A. Nitric oxide production depends on preceding tetrahydrobiopterin synthesis by endothelial cells: Selective suppression of induced nitric oxide production by sepiapterin reductase inhibitors. *Biochem Biophys Res Commun.* 1994;199:504-510
165. Klemm P, Hecker M, Stockhausen H, Wu CC, Thiemermann C. Inhibition by n-acetyl-5-hydroxytryptamine of nitric oxide synthase expression in cultured cells and in the anaesthetized rat. *Br J Pharmacol.* 1995;115:1175-1181
166. Schmidt K, Werner-felmayer G, Mayer B, Werner ER. Preferential inhibition of inducible nitric oxide synthase in intact cells by the 4-amino analogue of tetrahydrobiopterin. *Eur J Biochem.* 1999;259:25-31

167. Panda K, Rosenfeld RJ, Ghosh S, Meade AL, Getzoff ED, Stuehr DJ. Distinct dimer interaction and regulation in nitric-oxide synthase types i, ii, and iii. *J Biol Chem*. 2002;277:31020-31030
168. Du J, Teng RJ, Lawrence M, Guan T, Xu H, Ge Y, Shi Y. The protein partners of gtp cyclohydrolase i in rat organs. *PLoS One*. 2012;7:e33991
169. Krishnakumar S, Burton D, Rasco J, Chen X, O'Donnell J. Functional interactions between gtp cyclohydrolase i and tyrosine hydroxylase in drosophila. *J Neurogenet*. 2000;14:1-23
170. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, Sessa WC. Dynamic activation of endothelial nitric oxide synthase by hsp90. *Nature*. 1998;392:821-824
171. Sun X, Fratz S, Sharma S, Hou Y, Rafikov R, Kumar S, Rehmani I, Tian J, Smith A, Schreiber C, Reiser J, Naumann S, Haag S, Hess J, Catravas JD, Patterson C, Fineman JR, Black SM. C-terminus of heat shock protein 70-interacting protein-dependent gtp cyclohydrolase i degradation in lambs with increased pulmonary blood flow. *Am J Respir Cell Mol Biol*. 2011;45:163-171
172. Imazumi K, Sasaki T, Takahashi K, Takai Y. Identification of a rabphilin-3a-interacting protein as gtp cyclohydrolase i in pc12 cells. *Biochem Biophys Res Commun*. 1994;205:1409-1416
173. Hesslinger C, Kremmer E, Hultner L, Ueffing M, Ziegler I. Phosphorylation of gtp cyclohydrolase i and modulation of its activity in rodent mast cells. Gtp cyclohydrolase i hyperphosphorylation is coupled to high affinity ige receptor signaling and involves protein kinase c. *J Biol Chem*. 1998;273:21616-21622
174. Lapize C, Pluss C, Werner ER, Huwiler A, Pfeilschifter J. Protein kinase c phosphorylates and activates gtp cyclohydrolase i in rat renal mesangial cells. *Biochem Biophys Res Commun*. 1998;251:802-805
175. Harada T, Kagamiyama H, Hatakeyama K. Feedback regulation mechanisms for the control of gtp cyclohydrolase i activity. *Science*. 1993;260:1507-1510
176. Maita N, Hatakeyama K, Okada K, Hakoshima T. Structural basis of biopterin-induced inhibition of gtp cyclohydrolase i by gfrp, its feedback regulatory protein. *J Biol Chem*. 2004;279:51534-51540
177. Maita N, Okada K, Hatakeyama K, Hakoshima T. Crystal structure of the stimulatory complex of gtp cyclohydrolase i and its feedback regulatory protein gfrp. *Proc Natl Acad Sci U S A*. 2002;99:1212-1217
178. Auerbach G, Herrmann A, Bracher A, Bader G, Gutlich M, Fischer M, Neukamm M, Garrido-Franco M, Richardson J, Nar H, Huber R, Bacher A. Zinc plays a key role in human and bacterial gtp cyclohydrolase i. *Proc Natl Acad Sci U S A*. 2000;97:13567-13572
179. Higgins CE, Gross SS. The n-terminal peptide of mammalian gtp cyclohydrolase i is an autoinhibitory control element and contributes to binding the allosteric regulatory protein gfrp. *J Biol Chem*. 2011;286:11919-11928
180. Yoneyama T, Hatakeyama K. Decameric gtp cyclohydrolase i forms complexes with two pentameric gtp cyclohydrolase i feedback regulatory proteins in the presence of phenylalanine or of a combination of tetrahydrobiopterin and gtp. *J Biol Chem*. 1998;273:20102-20108
181. Leeming RJ, Blair JA, Green A, Raine DN. Biopterin derivatives in normal and phenylketonuric patients after oral loads of l-phenylalanine, l-tyrosine, and l-tryptophan. *Arch Dis Child*. 1976;51:771-777
182. Saunders-Pullman R, Blau N, Hyland K, Zschocke J, Nygaard T, Raymond D, Shanker V, Mohrmann K, Arnold L, Tabbal S, deLeon D, Ford B, Brin M, Chouinard S, Ozelius L, Klein C, Bressman SB. Phenylalanine loading as a diagnostic test for drd: Interpreting the utility of the test. *Mol Genet Metab*. 2004;83:207-212

183. Mitchell BM, Dorrance AM, Webb RC. Phenylalanine improves dilation and blood pressure in gtp cyclohydrolase inhibition-induced hypertensive rats. *J Cardiovasc Pharmacol*. 2004;43:758-763
184. Chavan B, Gillbro JM, Rokos H, Schallreuter KU. Gtp cyclohydrolase feedback regulatory protein controls cofactor 6-tetrahydrobiopterin synthesis in the cytosol and in the nucleus of epidermal keratinocytes and melanocytes. *J Invest Dermatol*. 2006;126:2481-2489
185. Werner ER, Bahrami S, Heller R, Werner-Felmayer G. Bacterial lipopolysaccharide down-regulates expression of gtp cyclohydrolase i feedback regulatory protein. *J Biol Chem*. 2002;277:10129-10133
186. Hattori Y, Nakanishi N, Kasai K, Murakami Y, Shimoda S. Tetrahydrobiopterin and gtp cyclohydrolase i in a rat model of endotoxic shock: Relation to nitric oxide synthesis. *Exp Physiol*. 1996;81:665-671
187. Tatham AL, Crabtree MJ, Warrick N, Cai S, Alp NJ, Channon KM. Gtp cyclohydrolase i expression, protein, and activity determine intracellular tetrahydrobiopterin levels, independent of gtp cyclohydrolase feedback regulatory protein expression. *J Biol Chem*. 2009;284:13660-13668
188. Nandi M, Kelly P, Vallance P, Leiper J. Over-expression of gtp-cyclohydrolase 1 feedback regulatory protein attenuates lps and cytokine-stimulated nitric oxide production. *Vasc Med*. 2008;13:29-36
189. Li L, Rezvan A, Salerno JC, Husain A, Kwon K, Jo H, Harrison DG, Chen W. Gtp cyclohydrolase i phosphorylation and interaction with gtp cyclohydrolase feedback regulatory protein provide novel regulation of endothelial tetrahydrobiopterin and nitric oxide. *Circ Res*. 2010;106:328-336
190. Naylor AM, Pojasek KR, Hopkins AL, Blagg J. The tetrahydrobiopterin pathway and pain. *Curr Opin Investig Drugs*. 2010;11:19-30
191. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. *Nature*. 2007;450:1001-1009
192. Jubb H, Higuera AP, Winter A, Blundell TL. Structural biology and drug discovery for protein-protein interactions. *Trends Pharmacol Sci*. 2012;33:241-248
193. Li L, Du Y, Chen W, Fu H, Harrison DG. A novel high-throughput screening assay for discovery of molecules that increase cellular tetrahydrobiopterin. *J Biomol Screen*. 2011;16:836-844